Halozyme Therapeutics Inc. diskutieren
Halozyme Therapeutics Inc.
WKN: A0DLHS / Symbol: HALO / Name: Halozyme / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
60,24 €
-1,34 %
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target raised by analysts at Benchmark Co. from $50.00 to $60.00. They now have a "buy" rating on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target lowered by analysts at JPMorgan Chase & Co. from $53.00 to $52.00. They now have an "overweight" rating on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target raised by analysts at Morgan Stanley from $59.00 to $64.00. They now have an "overweight" rating on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $60.00 price target on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at Cowen Inc.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $65.00 price target on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $68.00 price target on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $68.00 price target on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $68.00 price target on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target raised by analysts at HC Wainwright from $68.00 to $70.00. They now have a "buy" rating on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its price target raised by analysts at HC Wainwright from $70.00 to $72.00. They now have a "buy" rating on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $75.00 price target on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $72.00 price target on the stock.
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) was downgraded by analysts at Leerink Partners from a "market perform" rating to an "underperform" rating. They now have a $47.00 price target on the stock.
Ratings data for HALO provided by MarketBeat
Neueste Beiträge
SVB_Leerink_LLC in Tenet Healthcare diskutieren